We are live on ! Find out more
SLS icon

SELLAS Life Sciences
SLS

17 hedge funds and large institutions have $1.45M invested in SELLAS Life Sciences in 2019 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

55% more funds holding

Funds holding: 11 → 17 (+6)

0.71% more ownership

Funds ownership: 0.31% → 1.02% (+0.71%)

61% less capital invested

Capital invested by funds: $3.7M → $1.45M (-$2.26M)

Holders
17
Holders Change
+6
Holders Change %
+54.55%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
5
Reduced
3
Closed
1
Calls
$7K
Puts
–
Net Calls
+$7K
Net Calls Change
-$57K

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$2.79M
2
6CM
683 Capital Management
New York
+$1.67M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.22M
4
Deutsche Bank
Deutsche Bank
Germany
+$518K
5
AFM
Anson Funds Management
Texas
+$329K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$185K
2
BlackRock
BlackRock
New York
-$5.68K
3
Wells Fargo
Wells Fargo
California
-$426

SLS Hedge Fund Activity: Q2 2019 in Review

17 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q2 2019, worth a combined $1.45M — down 61% from $3.7M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new SLS positions and 1 closed out — a net gain of 6 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $2.79M. The largest seller was Vanguard Group, cutting an estimated $185K.

  • 17 institutional investors held SELLAS Life Sciences (SLS) as of Q2 2019, up from 11 in Q1 2019.
  • Funds reported $1.45M of SELLAS Life Sciences stock for Q2 2019, down 61% quarter-over-quarter.
  • 7 funds opened new SELLAS Life Sciences positions in Q2 2019 and 1 closed out, a net change of +6 holders.
  • The largest SELLAS Life Sciences buyer in Q2 2019 was Sabby Management, an estimated $2.79M added.
  • The largest SELLAS Life Sciences seller in Q2 2019 was Vanguard Group, an estimated $185K sold.

Based on aggregated 13F filings for Q2 2019.